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ABSTRACT
The incidence of non-albicans 
species of Candida has recently 
increased, especially in patients 
with malignant haematologi-
cal disorders receiving ﬂucona-
zole prophylaxis. A retrospective 
study of patients who developed 
candidaemia at Riyadh Armed 
Forces Hospital between Janu-
ary 1992 and December 2002 
was carried out. Thirty one epi-
sodes of candidaemia occurred 
in 27 patients with a variety of 
haematological disorders. Twen-
ty-four episodes were caused by 
non-albicans species of Candida 
and only 7 episodes were caused 
by C.albicans. The most frequent 
underlying haematological dis-
orders were acute myeloid leu-
kaemia (AML) followed by acute 
lymphoblastic leukaemia (ALL). 
The main predisposing factors for 
the development of candidaemia 
were: broad spectrum antibiotics, 
central venous catheters, neutro-
penia, cytotoxic chemotherapy, 
coexisting bacterial infections, 
steroid therapy, relapsing or un-
treated primary disease and ﬂu-
conazole prophylaxis.
Eight episodes were complicated 
by chronic disseminated candi-    www.ljm.org.ly   
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diasis. Amphotericin-B and amBi-
some were used in the treatment 
of Candida infections. The treat-
ment was successful in 86% of 
the episodes of C. albicans and 
50% of the episodes due to non-
albicans species of Candida. The 
highest mortality rate was en-
countered with C.tropicalis infec-
tions.
Candidaemia is an important 
cause of mortality and morbidity 
in patients with malignant hae-
matological disorders and stem 
cell transplant. The predomi-
nance of non-albicans species of 
Candida especially C.krusei and 
C.tropicalis is alarming. The early 
administration of appropriate an-
tifungal therapy and the removal 
of infected intravascular cathe-
ters improve the outcome consid-
erably.
INTRODUCTION
Most fungal infections in hospi-
talized patients are caused by 
Candida species. Recently, there 
has been a substantial shift in the 
epidemiology of haematogenous 
candidiasis caused by different 
species [1-5]. The use of prophy-
lactic ﬂuconazole is known to de-
crease colonization and subse-
quent infection with C. albicans 
[6,7]. However, the extensive use 
of this drug in neutropenic pa-
tients with leukaemia and stem 
cell transplant (SCT) has been 
associated with the emergence of 
azole-resistant non-albicans spe-
cies of Candida [3-5,8-11].
Blood cultures for Candida be-
come positive at a median time of 
10 days after the onset of neutro-
penia [12]. Polymerase chain re-
actions (PCR) and antigen detec-
tion tests are useful in making an 
early diagnosis of candidaemia 
[13,14]. Successful management 
of candidaemia depends upon the 
early institution of antifungal ther-
apy, the recovery of neutrophilic 
count and the early removal of 
intravascular catheters if present 
[12,15,16].
A previous study done at our insti-
tution demonstrated the predomi-
nance of non-albicans Candida 
in the bloodstream isolates in the 
haematology unit with C. krusei 
being the commonest Candida 
species encountered [17]. In view 
of that study and similar reports 
on the prevalence of non-albicans 
species of Candida in neutropenic 
patients with malignant haemato-
logical disorders, this retrospec-
tive study was conducted.Libyan Journal of Medicine, Volume 1, 2006
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PATIENTS, MATERIALS AND 
METHODS
Riyadh Armed Forces Hospital 
(RAFH) is a tertiary care center 
comprising 1200 beds with spe-
cialty services including: inten-
sive care, haematology/oncology, 
SCT and solid organ transplanta-
tion. A retrospective study of pa-
tients with various haematologic 
disorders and SCT who devel-
oped candidaemia at RAFH be-
tween January 1992 and Decem-
ber 2002 was carried out. The 
medical records and the labora-
tory data of these patients were 
reviewed.
DEFINITIONS
Candidaemia: The presence of 
a clinical illness (eg. fever, hypo-
tension or respiratory insufﬁcien-
cy) associated with the isolation 
of Candida species from at least 
one blood culture specimen, with-
out evidence of visceral involve-
ment. An episode was regarded 
as having at least one positive 
blood culture set for a single Can-
dida species during one period of 
hospitalization. All the consecu-
tive positive blood cultures with-
in 72 hours for the same type of 
Candida during the same period 
of hospitalization were consid-
ered as a single episode. If more 
than one Candida species were 
isolated during the same period 
of hospitalization, infection due to 
each species was considered a 
separate episode.
Breakthrough fungaemia: The 
presence of Candida in the blood-
stream of patients who have re-
ceived prophylactic systemic an-
tifungal therapy for longer than 48 
hours.
Persistent infection: The pres-
ence of Candida in blood culture 
specimens 72 hours or longer af-
ter starting appropriate antifungal 
therapy. All patients with persist-
ent fungaemia were evaluated for 
secondary ocular, cardiovascular 
or joint infections.
Chronic disseminated candi-
diasis (CDC): The presence of 
histopathological evidence (bud-
ding yeast or pseudohyphae) of 
candidiasis in the spleen, the liver 
and the kidneys and/or radiologi-
cal evidence (hypodense lesions) 
of hepatosplenic or renal candi-
diasis.
Acute disseminated candidia-
sis (ADC): Patients having evi-
dence of multiple noncontagious 
organ infection acquired through 
haematogenous spread i. e. 
the presence of fungal infection 
(based on histology or culture) in 
a certain body organ and having 
clinical, histopathological or ra-
diological evidence of the same     www.ljm.org.ly   
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fungal infection in another organ.
Catheter–related candidiasis: 
Candidaemia was considered to 
be catheter related if there is no 
apparent source of infection or if 
the organism was isolated from 
both central and peripheral blood 
culture specimens or if the organ-
ism was isolated form both a pe-
ripheral blood culture specimen 
and the tip of the central venous 
catheter.
Colonization by Candida spe-
cies: Positivity of surveillance 
cultures performed from nasal, 
pharyngeal, rectal, urinary and 
skin swabs.
Other coexisting infections: 
The presence of other organisms 
(eg. bacteria, viruses or other fun-
gal species) causing a clinically 
signiﬁcant illness.
Neutropenia: Absolute neu-
trophilic count (ANC) <500 cells/
mm3 in the peripheral circulation 
was regarded as neutropenia 
and ANC <100 cells/mm3 was 
regarded as profound or severe 
neutropenia. Duration of neutro-
penia was deﬁned as the time 
interval in days form the onset of 
neutropenia till the detection of 
Candida species in blood culture 
specimens.
Febrile illness: More than two 
successive oral readings of great-
er than or equal to 38OC within 
24 hours period. 
Therapeutic response (to both 
initial and subsequent thera-
py): The complete resolution of 
all signs and symptoms of infec-
tion and the presence of negative 
blood cultures for Candida.
Therapeutic failure: Failure of 
antifungal therapy to eliminate 
candidaemia within 3 days or no 
improvement or worsening of clin-
ical manifestations after 3 days of 
antifungal therapy.
Mortality: Death attributable to 
fungaemia was considered when 
patients died with clinical, micro-
biological or histopathological evi-
dence of active fungal infection in 
the absence of other identiﬁable 
causes of death.
MICROBIOLOGICAL TECH-
NIQUES
The diagnosis of candidaemia 
was based on the isolation of the 
yeast from one or more blood cul-
ture sets (aerobic and/or anaero-
bic bottles) collected from pa-
tients with various haematological 
disorders having febrile illness or 
clinical evidence of septic shock. 
Blood cultures were performed 
using the automated blood cul-
ture system (Bactec 9240, Beck-
ton Dickinson, USA]. Presump-
tive identiﬁcation was done by the 
use of germ tube reaction, colo-
ny morphology and colour reac-Libyan Journal of Medicine, Volume 1, 2006
page
144
    www.ljm.org.ly   
ljm
tion on chrom agar [Chrom Agar 
Technology, Paris]. Identiﬁcation 
to species level was done by the 
commercial identiﬁcation system 
API 20C [Analytic Products, plain 
view, NY, USA]. For CVC (cen-
tral venous catheter) tip culture, 
a semiqunatitative culture meth-
od was used where > 15 colony 
forming units were considered 
signiﬁcant.
RESULTS
Thirty one episodes of candidae-
mia were encountered in twenty-
seven patients over an eleven 
year period (January 1992 to De-
cember 2002). One patient expe-
rienced three episodes of candi-
daemia with different species and 
two patients developed two epi-
sodes of fungaemia each. All the 
records of these patients were re-
trieved for analysis. All the posi-
tive blood cultures were thought 
to represent true infection rather 
than contamination. The distribu-
tion of the episodes of candidae-
mia over the study period of time 
is shown in Figure 1. 
Figure 1: Shows the distribution of the 
episodes of candidaemia
Of the patients studied, 14 were 
males and 13 were females. The 
ages of these patients ranged 
between 16 and 72 years (mean:     www.ljm.org.ly   
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36.8 years). Thirteen patients 
had AML, 10 had ALL, 2 non–
Hodgkin’s lymphoma, 1 multiple 
myeloma and 1 beta-thalassae-
mia major. Only 5 patients had 
SCT prior to the candidaemic 
episodes (4 allogeneic and 1 au-
tologous). The overall incidence 
of candidaemia at our institution 
during the period of the study was 
10.45% in patients with acute leu-
kaemia and 4.4% in patients with 
SCT. Breakthrough fungaemia 
was seen in 15 episodes (2 epi-
sodes were caused by C.albicans 
and 13 episodes were caused by 
non-albicans species of Candida) 
during which patients were re-
ceiving ﬂuconazole prophylaxis.
Acute disseminated candidiasis 
complicated one episode of fun-
gaemia caused by C. krusei spe-
cies. Only three episodes of can-
didaemia were complicated by 
persistent fungal infections (two 
with C. krusei and one with C. 
tropicalis). Amphotericin-B was 
used in the treatment of 19 of the 
episodes of fungaemia. The dose 
of amphotericin-B used was 1 mg 
per kg per day intravenously over 
4 to 6 hours. Only 3 fungaemic 
episodes were treated with intra-
lipid formulations of amphotericin-
B (Abelcet; Enzon). Liposomal 
amphotericin-B (amBisome) was 
used in the treatment of 9 epi-
sodes of candidaemia and it was 
predominantly used in case of re-
nal impairment or disseminated 
fungal infection. The doses of 
amBisome used were 3 to 5 mg 
per kg per day intravenously over 
30 minutes. The duration of anti-
fungal therapy was 2 to 3 weeks 
for uncomplicated candidaemia 
and 2 to 4 months for chronic dis-
seminated candidiasis (CDC). 
Four cases of CDC were treated 
with amphotericin-B and 4 cases 
were treated with amBisome. All 
the patients who developed can-
didaemia and were having ind-
welling intravascular catheters in 
situ at the time of the fungaemic 
episode had removal of these de-
vices. 
Early removal of intravascular 
catheters (within 12 hours) was 
performed in 21 episodes, while 
late removal was done in the re-
maining 10 episodes of fungae-
mia. All 5 episodes of fungaemia 
due to C. albicans, during which 
early removal of indwelling intra-
vascular devices was possible, 
ultimately had successful out-
come, while only 10 of 16 epi-
sodes of non-albicans candidae-
mia, during which early removal 
of intravascular catheters was 
done, had successful outcomes. 
The predisposing factors for the 
development of candidaemia are Libyan Journal of Medicine, Volume 1, 2006
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shown in Table 1.
Neutropenia, radiotherapy, ster-
oid therapy and coexisting bacte-
rial infections were more frequent 
with C. albicans infections while 
old age, other medical illness-
es, relapsing disease, cytotoxic 
chemotherapy and ﬂuconazole 
prophylaxis were more frequently 
encountered in episodes caused 
by non-albicans species. The 
coexisting bacterial infections 
were predominantly caused by 
gram negative organisms: Pseu-
domonas aeruginosa, Stenotro-
phomonas maltophilia, Klebseilla 
pneumoniae and E. coli. Com-
pared to patients having fungae-
mia due to other types of non-
albicans Candida, patients with 
C. krusei had a lower proportion 
of coexisting bacterial infections 
(41.7%) and a higher percent-
age of ﬂunconazole use (75%). 
Nine patients with candidaemia 
(33.3%) had surgical intervention 
prior to the episodes of fungae-
mia. Twenty episodes of fungae-
mia (64.5%) were preceeded by 
mucous membrane colonization. 
Relapsing primary haematologi-
cal disorder was found to be a 
signiﬁcant risk factor for the de-
velopment of candidaemia (Fish-
er’s exact, two sided p= 0.02). 
Successful management of the 
candidaemic episodes was high-
er in C. albicans than in the oth-
er types of Candida (85.7% vs. 
50%). Amongst the non-albicans 
species of Candida, the best out-
come of treatment of the episodes 
of fungaemia was encountered 
with C. parapsillosis (100%). One 
year follow up of the 27 patients 
studied showed that 22 patients 
died and only 5 patients survived. 
The details are shown in Table 
2.
Fungaemia was the primary 
cause of death in 37.5% of pa-
tients with non-albicans candi-
daemia but was the sole cause 
of death in one patient with C. 
albicans sepsis. The underlying 
haematological disorder and the 
development of other infections 
were the main causes of death in 
the deceased patients with C. al-
bicans infections. Eight episodes 
of fungaemia were complicated 
by CDC (4 C. albicans and 4 non-
albicans Candida species). In pa-
tients with CDC, the liver and the 
spleen were the most frequently 
involved internal body organs 
while involvement of the kidneys 
was encountered in only two epi-
sodes of candidaemia (Table 3).
DISCUSSION
Candida species are the most 
common cause of fungal infec-L
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tions and they produce infections 
that range from non-life threat-
ening mucocutaneous illnesses 
to invasive processes that may 
eventually involve any body or-
gan [9,16]. Candidaemia is a 
serious complication and an im-
portant cause of morbidity and 
mortality in patients with acute 
leukaemia, various forms of stem 
cell and solid organ transplanta-
tion [8-10,16]. The predisposing 
factors for candidaemia include: 
malignant haematological disor-
ders specially AML, stem cell and 
solid organ transplantation, in-
tensive cytotoxic chemotherapy, 
prolonged neutropenia, intravas-
cular catheters, steroid therapy, 
broad spectrum antibiotic treat-
ment, antifungal prophylaxis with 
ﬂuconazole, bacteremia, cytome-
galovirus disease, hospitalization 
and admission to intensive care 
units, HIV infection, surgical in-
tervention and fetal immaturity 
[5,12,13,15,18-21]. Gastrointesti-
nal colonization by Candida spe-
cies has also been found to play 
a major role in the development 
of breakthrough candidaemia 
[5,8,15,22-24]. In addition, re-
lapsing, untreated and refractory 
primary disease is an important 
associated factor for the develop-
ment of fungaemia [25]. The pre-
dominant clinical manifestations 
of candidaemia are: fever, skin 
lesions, respiratory symptoms 
and septic shock [12,15,20]. In 
our study, the main predispos-
ing factors for the development of 
fungaemia were: malignant hae-
matological disorders specially 
AML, broad spectrum antibiotics, 
central venous catheters, neutro-
penia, cytotoxic chemotherapy, 
coexisting bacterial infection and 
steroid therapy. In agreement 
with similar studies, ﬂuconazole 
prophylaxis, mucocutaneous 
colonization by Candida, and re-
lapsing primary malignant hae-
matological disorder were found 
to be important predisposing fac-
tors for candidaemia, particularly 
in patients with fungaemia due to 
non-albicans species.
Previously, C. albicans was found 
to be the commonest cause of 
candidaemia, but in recent years 
approximately 50% of the fun-
gaemic episodes were caused 
by other Candida species [8-10]. 
Patients with C. albicans sepsis 
often have other co-existing viral 
and bacterial infections and septic 
thrombophlebitis and have a sig-
niﬁcantly greater overall response 
to antifungal therapy and to the 
treatment given for the primary 
illness [8]. Non-albicans Candi-
da species particularly C. krusei 
and C. glabrata have recently 
emerged as important causes of     www.ljm.org.ly   
page
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candidaemia among neutropenic 
cancer or SCT patients who have 
received ﬂuconazole prophylaxis 
[5,8,10,22]. They may be intrin-
sically resistant to ﬂuconazole, 
but they are very susceptible to 
amphotericin-B and the new ex-
tended spectrum triazoles such 
as voriconazole and posacona-
zole [9,22,26]. The frequency of 
non-albicans Candida species 
as causes of bloodstream iso-
lates and their susceptibilities to 
ﬂuconazole, vary considerably 
among different countries world-
wide [8,17,26,27]. Fungaemia, 
due to these organisms, carries 
high mortality rates in immuno-
compromised individuals, espe-
cially in patients with leukaemia, 
solid tumors and hepatic disor-
ders [8,15,17,21,26,27]. As with 
reports of increased prevalence 
of non-albicans species of Can-
dida in neutropenic patients, our 
study showed predominance of 
non-albicans species particularly 
C. krusei and C. tropicalis.
Over the past two decades, there 
has been a gradual increase in 
the number of patients with ma-
lignant haematological disorders 
at risk of invasive fungal infec-
tions [8,28,29]. Although CDC is 
a life threatening complication in 
immunocompromised individuals, 
the mortality rates due to CDC 
are less than that encountered 
in candidaemia and invasive as-
pergillosis [18,28]. Only one ﬁfth 
of the cases of CDC have positive 
blood cultures due to previous 
exposure to antifungal therapy 
or prophylaxis [23]. Studies have 
shown that the liver, the spleen, 
the lungs and the kidneys are the 
most frequently involved body or-
gans [18]. Our study showed that 
disseminated Candida infections 
were seen more frequently with 
C. albicans and that the liver, the 
spleen and the kidneys were the 
most commonly involved body 
sites.
In many laboratories, the suscep-
tibility testing of fungi is not consid-
ered a routine testing procedure 
[16]. It is most helpful in dealing 
with severe and invasive fungal 
infections due to non-albicans 
species of Candida [9,10,16]. Es-
pecially in patients treated with 
azole antifungal agents, the pos-
sibility of microbiological resist-
ance should be taken into con-
sideration [9-11,16,26,27]. Azole 
resistance for C. albicans has 
been reported in patients with 
HIV infection and in patients with 
invasive candidiasis [9-11,16].
Despite its adverse effects, con-
ventional amphotericin-B has 
been the standard agent for the Libyan Journal of Medicine, Volume 1, 2006
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treatment of invasive candidiasis 
[5,10,16]. Amphotericin-B related 
nephrotoxicity and other side ef-
fects have been associated with 
increased mortality, thus making 
the various lipid formulations of 
amphotericin-B more appropri-
ate alternatives [16]. Most Can-
dida isolates appear to remain 
susceptible to amphotericin-B al-
though recent data indicate that 
C. krusei and C. glabrata may re-
quire relatively high doses of am-
photericin-B [10,16]. In patients 
with febrile neutropenia, amBi-
some has comparable efﬁcacy to 
conventional amphotericin-B and 
is associated with fewer break-
through fungal infections and less 
nephrotoxicity and other side ef-
fects [30]. Caspofungin is as ef-
fective as amphotericin-B in the 
treatment of candidaemia and 
invasive Candida infections [31]. 
Flucytosine is active against many 
Candida isolates but its adverse 
effects have limited its use [16]. 
Despite the recent advances in 
antifungal therapy, intense efforts 
are still required to develop more 
effective antifungal agents for use 
in the treatment of severe and in-
vasive fungal infections [32]. The 
late introduction of the new anti-
fungal agents (voriconazole and 
caspofungin) at our institution 
and the avoidance of ﬂucytosine 
use due to its myelotoxicity made 
various amphotericin-B formula-
tions the cornerstone of therapy 
for the candidaemic episodes dis-
cussed.
In patients with fungaemia, poor 
prognosis and high mortality 
rates are associated with: severe 
underlying illness, old age, pro-
longed neutropenia, culture of 
non-albicans species of Candida, 
septic shock, visceral dissemina-
tion and lack of antifungal proph-
ylaxis [2,15,33]. The early recog-
nition of candidaemia, the prompt 
removal of central venous cath-
eters and the early initiation of 
an appropriate antifungal therapy 
improve the outcome of patients 
with candidaemia [15,34]. In our 
group of patients: prolonged neu-
tropenia, untreated or relapsing 
primary disease, septic shock and 
the presence of non-albicans fun-
gaemia were the leading causes 
of unsuccessful outcome.
CONCLUSION
Candidaemia is an important 
cause of morbidity and mortality 
in patients with malignant haema-
tological disorders and SCT. The 
use of ﬂuconazole prophylaxis 
in neutropenic immunocompro-
mised individuals is associated 
with the emergence of non-albi-
cans species of Candida. Suc-    www.ljm.org.ly   
page
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cessful outcome of candidaemia 
depends upon the early adminis-
tration of appropriate antifungal 
therapy and the early removal of 
infected intravascular devices, 
while the delayed recovery of neu-
tropenia and the culture of non-
albicans species of Candida are 
associated with poor prognosis. 
In patients with candidaemia, it is 
mandatory to perform repeated 
and thorough clinical assessment 
and to repeat appropriate sero-
logical and radiological investiga-
tions to rule out the possibility of 
disseminated candidiasis.
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